{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:04:45Z","timestamp":1776276285970,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011203.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000}}],"reference-count":104,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011203.pub3","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T19:03:47Z","timestamp":1686164627000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alemtuzumab for multiple sclerosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Rachel","family":"Riera","sequence":"additional","affiliation":[{"name":"Cochrane Brazil Rio de Janeiro; Petr\u00f3polis Medical School; Petr\u00f3polis Brazil"},{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade (Nepsbeats); Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Regina","family":"Torloni","sequence":"additional","affiliation":[{"name":"Cochrane Brazil; Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Luiza C","family":"Martimbianco","sequence":"additional","affiliation":[{"name":"Cochrane Brazil Rio de Janeiro; Petr\u00f3polis Medical School; Petr\u00f3polis Brazil"},{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade (Nepsbeats); Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Postgraduate Program in Health and Environment; Universidade Metropolitana de Santos (UNIMES); Santos Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael L","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Cochrane Brazil Rio de Janeiro; Petr\u00f3polis Medical School; Petr\u00f3polis Brazil"},{"name":"Center of Health Technology Assessment; Hospital S\u00edrio-Liban\u00eas; S\u00e3o Paulo Brazil"},{"name":"N\u00facleo de Ensino e Pesquisa em Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o de Tecnologias em Sa\u00fade (Nepsbeats); Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"},{"name":"Centro Universit\u00e1rio S\u00e3o Camilo; S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD011203.pub3-BIB0001|cit1","first-page":"S135","article-title":"Alemtuzumab reverses pre-existing disability in relapsing-remitting multiple sclerosis patients independent of relapse history","volume":"15","author":"Coles","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"17","key":"10.1002\/14651858.CD011203.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1069\u201378","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011203.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(11)70020-5","article-title":"Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes","volume":"10","author":"Coles","year":"2011","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jns.2016.02.025","article-title":"Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients","volume":"363","author":"Fox","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD011203.pub3-BIB0007|cit7","first-page":"S140","article-title":"Alemtuzumab's efficacy in the CAMMS223 trial as assessed with the Multiple Sclerosis Severity Score","volume":"16","author":"Herbert","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0008|cit8","unstructured":"A phase II study comparing low- and high-dose alemtuzumab and high-dose Rebif\u00ae in patients with early, active relapsing-remitting multiple sclerosis clinicaltrials.gov\/ct2\/show\/NCT00050778"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0009|cit9","first-page":"S11.006","article-title":"Effect of alemtuzumab vs. RebifTM on brain MRI measurements: results of CARE-MS I, a phase 3 study","volume":"78","author":"Arnold","year":"2012","journal-title":"Neurology"},{"issue":"14","key":"10.1002\/14651858.CD011203.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \u03b2-1a in MS","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD011203.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1177\/1352458516677589","article-title":"Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis","volume":"23","author":"Arroyo Gonz\u00e1lez","year":"2017","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/j.jns.2013.07.1366","article-title":"Alemtuzumab improves visual outcomes in treatment-na\u00efve patients with relapsing\u2013remitting multiple sclerosis (RRMS): analysis from the phase 3 CARE-MS I study","volume":"333","author":"Balcer","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"9856","key":"10.1002\/14651858.CD011203.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0014|cit14","first-page":"S01.006","article-title":"Efficacy and safety results from comparison of alemtuzumab and RebifTM efficacy in multiple sclerosis I (CARE-MS I): a phase 3 study in relapsing-remitting treatment-naive patients","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"PD5.004","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.PD5.004","article-title":"Relapse outcomes with alemtuzumab vs. RebifTM in treatment-naive relapsing-remitting multiple sclerosis (CARE-MS I): secondary and tertiary endpoints","volume":"78","author":"Fox","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0016|cit16","first-page":"47","article-title":"Disease activity-free status in comparison of alemtuzumab and RebifTM efficacy in multiple sclerosis I (CARE-MS I) phase 3 study","volume":"259","author":"Giovannoni","year":"2012","journal-title":"Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0017|cit17","first-page":"S66","article-title":"Thyroid autoimmunity in comparison of alemtuzumab and RebifTM efficacy in multiple sclerosis studies I and II","volume":"259","author":"Habek","year":"2012","journal-title":"Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0018|cit18","first-page":"S41.007","article-title":"Infections Phase 3 study: comparison of alemtuzumab and RebifTM efficacy in multiple sclerosis I (CARE-MS I)","volume":"78","author":"Havrdova","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD011203.pub3-BIB0019|cit19","first-page":"S151","article-title":"Alemtuzumab for relapsing-remitting multiple sclerosis: CARE-MS I baseline demographics and disease characteristics","volume":"16","author":"Havrdova","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.jns.2013.07.1365","article-title":"Adverse event profile of alemtuzumab over time in treatment-naive patients with early, active relapsing-remitting multiple sclerosis (RRMS; CARE-MS I study)","volume":"333","author":"Lycke","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0021|cit21","unstructured":"Lycke J Arnold DL Cohen JA Coles AJ Fox EJ Hartung HP Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up 29th Congress or the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2013 Oct 2-5; Copenhagen, Denmark 2013"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0022|cit22","first-page":"P01.173","article-title":"Detection, incidence, and management of thyroid autoimmunity in comparison of alemtuzumab and RebifTM in multiple sclerosis (CARE-MS) I and II","volume":"80","author":"Miller","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0023|cit23","unstructured":"Comparison of alemtuzumab and Rebif\u00ae efficacy in multiple sclerosis, study one (CARE-MS I) clinicaltrials.gov\/ct2\/show\/NCT00530348"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0024|cit24","first-page":"S41.006","article-title":"Incidence of autoimmunity in a phase 3 trial: comparison of alemtuzumab and RebifTM in multiple sclerosis I (CARE-MS I)","volume":"78","author":"Selmaj","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0025|cit25","first-page":"S65","article-title":"Alemtuzumab improves patient-reported quality of life in relapsing-remitting multiple sclerosis: CARE-MS I and II phase 3 trials","volume":"259","author":"Selmaj","year":"2012","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011203.pub3-BIB0026|cit26","first-page":"397","article-title":"Effect of alemtuzumab vs. Rebif\u00ae on brain MRI measurements","volume":"18","author":"Arnold","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"14","key":"10.1002\/14651858.CD011203.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \u03b2-1a in MS","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD011203.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1177\/1352458516677589","article-title":"Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis","volume":"23","author":"Arroyo Gonz\u00e1lez","year":"2017","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0029|cit29","first-page":"S121","article-title":"Alemtuzumab improves quality of life compared to SC IFNB-1a in CARE-MS II","volume":"260","author":"Arroyo","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0030|cit30","first-page":"126","article-title":"Alemtuzumab demonstrates improvement in MRI outcomes across baseline subgroups versus subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy","volume":"21","author":"Barkhof","year":"2014","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0031|cit31","first-page":"100","article-title":"Alemtuzumab improves MRI outcomes regardless of subgroup versus interferon beta-1a in relapsing remitting MS patients who relapsed on prior therapy","volume":"28","author":"Barkhof","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"S1","key":"10.1002\/14651858.CD011203.pub3-BIB0032|cit32","first-page":"283","article-title":"Alemtuzumab improves Expanded Disability Status Scale (EDSS) via effects on functional systems: CARE-MS II. Multiple Sclerosis","volume":"19","author":"Brinar","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"CN","DOI":"10.1212\/WNL.78.1","article-title":"Efficacy and safety results from comparison of alemtuzumab and Rebif efficacy in multiple sclerosis II (CARE-MS II): a phase 3 study in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy","volume":"78","author":"Cohen","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0035|cit35","first-page":"458","article-title":"Efficacy of alemtuzumab in relapsing remitting multiple sclerosis (RRMS) patients with highly active disease despite therapy","volume":"19","author":"Confavreux","year":"2012","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0036|cit36","first-page":"S14","article-title":"Alemtuzumab improves disability by month 6 independent of relapse history in relapsing-remitting multiple sclerosis patients: CARE-MS II 20620","volume":"260","author":"Fernandez","year":"2013","journal-title":"Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0037|cit37","first-page":"67","article-title":"Alemtuzumab improves MRI outcomes in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: three-year follow-up of CARE-MS II","volume":"20","author":"Fisher","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"S1","key":"10.1002\/14651858.CD011203.pub3-BIB0038|cit38","first-page":"419","article-title":"Disability improvement with alemtuzumab vs. interferon b- 1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II)","volume":"18","author":"Giovannoni","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0039|cit39","first-page":"P07.120","article-title":"Disability improvement with alemtuzumab vs. interferon beta-1a in relapsing-remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE-MS II)","volume":"80","author":"Giovannoni","year":"2013","journal-title":"Neurology"},{"issue":"19","key":"10.1002\/14651858.CD011203.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","article-title":"Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients","volume":"87","author":"Giovannoni","year":"2016","journal-title":"Neurology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0041|cit41","first-page":"I7","article-title":"Alemtuzumab improves visual outcomes vs. subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis (RRMS) who relapsed on prior therapy: analysis from the CARE-MS II study","volume":"82","author":"Graves","year":"2014","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0042|cit42","first-page":"S66","article-title":"Thyroid autoimmunity in comparison of alemtuzumab and RebifTM efficacy in multiple sclerosis studies I and II","volume":"259","author":"Habek","year":"2012","journal-title":"Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0043|cit43","first-page":"P07.093","article-title":"Alemtuzumab reduces MS disease activity in active relapsing-remitting multiple sclerosis patients who had disease activity on prior therapy","volume":"80","author":"Hartung","year":"2013","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0044|cit44","first-page":"S47","article-title":"Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE-MS II","volume":"259","author":"Hartung","year":"2012","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011203.pub3-BIB0045|cit45","first-page":"235","article-title":"Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II)","volume":"18","author":"Havrdova","year":"2012","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0046|cit46","first-page":"S120","article-title":"Lymphocyte counts and infection risk among relapsing remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)","volume":"260","author":"Havrdova","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0047|cit47","unstructured":"Comparison of alemtuzumab and Rebif\u00ae efficacy in multiple sclerosis, study two www.isrctn.com\/ISRCTN70702834"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD011203.pub3-BIB0048|cit48","first-page":"P07.125","article-title":"Anti-IFNB-1A antibody status was not a factor influencing efficacy of alemtuzumab vs IFNB-1A in relapsing-remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE-MS II)","volume":"80","author":"Khan","year":"2013","journal-title":"Neurology"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD011203.pub3-BIB0049|cit49","first-page":"P01.174","article-title":"Adverse event profile of alemtuzumab over time in active relapsing-remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE-MS II)","volume":"80","author":"LaGanke","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.jns.2013.07.1365","article-title":"Adverse event profile of alemtuzumab over time in treatment-na\u00efve patients with early, active relapsing-remitting multiple sclerosis (RRMS; CARE-MS I study)","volume":"333","author":"Lycke","year":"2013","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0051|cit51","first-page":"487","article-title":"Adverse event profile of alemtuzumab in active relapsing remitting multiple sclerosis patients who participated in the CARE-MS studies: three-year follow-up","volume":"19","author":"Lycke","year":"2013","journal-title":"29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2-5 October 2013, Copenhagen, Denmark"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0052|cit52","first-page":"P01.173","article-title":"Detection, incidence, and management of thyroid autoimmunity in comparison of alemtuzumab and RebifTM in multiple sclerosis (CARE-MS) I and II","volume":"80","author":"Miller","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0053|cit53","first-page":"86","article-title":"Alemtuzumab improves quality of life in relapsing remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II","volume":"20","author":"Moreau","year":"2014","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0054|cit54","unstructured":"Comparison of alemtuzumab and Rebif\u00ae efficacy in multiple sclerosis, study two (CARE-MS II) clinicaltrials.gov\/ct2\/show\/NCT00548405"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0055|cit55","first-page":"S65","article-title":"Alemtuzumab improves patient-reported quality of life in relapsing-remitting multiple sclerosis: CARE-MS I and II phase 3 trials","volume":"259","author":"Selmaj","year":"2012","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0056|cit56","first-page":"281","article-title":"Alemtuzumab significantly improves disability in patients with active relapsing-remitting MS and an inadequate response to prior therapy as assessed using a novel, composite measure: confirmed disability improvement-plus: results from CARE-MS II","volume":"22","author":"Singer","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD011203.pub3-BIB0057|cit57","first-page":"P07.101","article-title":"Immunogenicity of alemtuzumab treatment in relapsing-remitting multiple sclerosis (RRMS) patients in the CARE-MS II study","volume":"80","author":"Soelberg-Sorensen","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011203.pub3-BIB0058|cit58","first-page":"P01.172","article-title":"Comparison of infection risk with alemtuzumab and sc IFNB-1a in patients with multiple sclerosis who experienced disease activity while on prior therapy (CARE-MS II)","volume":"80","author":"Wray","year":"2013","journal-title":"Neurology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD011203.pub3-BIB0059|cit59","first-page":"P07.098","article-title":"Relapse outcomes with alemtuzumab vs IFNB-1A in active relapsing-remitting multiple sclerosis patients who experienced disease activity while on prior therapy (CARE-MS II)","volume":"80","author":"Wyman","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0060|cit60","unstructured":"Canadian Agency for Drugs and Technologies in Health Management of relapsing-remitting multiple sclerosis www.ncbi.nlm.nih.gov\/books\/NBK169748\/"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011203.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0065|cit65","unstructured":"European Medicines Agency Lemtrada \u2013 Committee for Medicinal Products for Human Use (CHMP) \u2013 assessment report www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003718\/WC500150522.pdf"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0066|cit66","unstructured":"Campath (alemtuzumab) Product Approval Information \u2013 application number BLA 103948\/0 www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/103948_0000_Campath_AprvbleLtr2.pdf"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0067|cit67","unstructured":"Alemtuzumab (Lemtrada) product approval information. Licensing Action 2014 www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/103948Orig1s5139ltr.pdf"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0068|cit68","unstructured":"Risk Evaluation and Mitigation Strategies (REMS). Lemtrada 2015 www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=IndvRemsDetails.page&REMS=340"},{"issue":"6","key":"10.1002\/14651858.CD011203.pub3-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135245859900500410","article-title":"Recent developments in the assessment of quality of life in multiple sclerosis (MS)","volume":"5","author":"Fischer","year":"1999","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0071|cit71","unstructured":"Genzyme: Peripheral and Central Nervous System Drugs Advisory Committee Alemtuzumab Advisory Committee Briefing Document. BLA 103948 www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM374188.pdf"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of campath-1h antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00005-012-0164-3","article-title":"Antibodies in the treatment of aplastic anaemia","volume":"60","author":"Gomez-Almaguer","year":"2012","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0074|cit74","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"2","key":"10.1002\/14651858.CD011203.pub3-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003208.pub2","article-title":"Methotrexate for multiple sclerosis","author":"Gray","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp.67.2.148","article-title":"Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors","volume":"67","author":"Hawkins","year":"1999","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"189624","DOI":"10.1155\/2013\/189624","article-title":"Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis","volume":"2013","author":"Healy","year":"2013","journal-title":"Multiple Sclerosis International"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0078|cit78","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0079|cit79","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 (updated February 2021). Cochrane Collaboration, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD011203.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00415-008-0696-y","article-title":"Campath1-H treatment in patients with aggressive relapsing remitting multiple sclerosis","volume":"255","author":"Hirst","year":"2008","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","article-title":"Magnetic resonance imaging results of the PRISMS trial: a randomised, double-blind, placebo-controlled study of interferon-beta la in relapsing\u2013remitting multiple sclerosis","volume":"46","author":"Li","year":"1999","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH-1H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0089|cit89","unstructured":"Multiple Sclerosis International Federation (MSIF) Global economic impact of multiple sclerosis www.msif.org\/wp-content\/uploads\/2014\/09\/Global_economic_impact_of_MS.pdf"},{"issue":"13","key":"10.1002\/14651858.CD011203.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011203.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011203.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0094|cit94","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011203.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-510X(09)70012-7","article-title":"Concepts of induction and escalation therapy in multiple sclerosis","volume":"277","author":"Rieckmann","year":"2009","journal-title":"Journal of Neurosurgical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD011203.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Practical Neurology"},{"issue":"9","key":"10.1002\/14651858.CD011203.pub3-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011203.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1098\/rstb.2005.1702","article-title":"Campath: from concept to clinic","volume":"360","author":"Waldmann","year":"2005","journal-title":"Philosophical transactions of the Royal Society B: Biological Sciences"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/imt.10.68","article-title":"Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation","volume":"2","author":"Weissenbacher","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1002\/14651858.CD011203.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/eji.1830210714","article-title":"Characterization of the Campath-1 (CDW2) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone","volume":"21","author":"Xia","year":"1991","journal-title":"European Journal of Immunology"},{"issue":"11","key":"10.1002\/14651858.CD011203.pub3-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010968.pub2","article-title":"Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis","author":"Zhang","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011203.pub3-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011203","article-title":"Alemtuzumab for multiple sclerosis","author":"Riera","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011203.pub3-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011203.pub2","article-title":"Alemtuzumab for multiple sclerosis","author":"Riera","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:33:46Z","timestamp":1729067626000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011203.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":104,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011203.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}